| Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution C Abbosh, NJ Birkbak, GA Wilson, M Jamal-Hanjani, T Constantin, ... Nature 545 (7655), 446-451, 2017 | 1743 | 2017 |
| Outcomes of COVID-19 in patients with CLL: a multicenter international experience AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ... Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020 | 312 | 2020 |
| A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies HS Walter, SA Rule, MJS Dyer, L Karlin, C Jones, B Cazin, P Quittet, ... Blood, The Journal of the American Society of Hematology 127 (4), 411-419, 2016 | 286 | 2016 |
| Curcumin combined with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase IIa trial LM Howells, COO Iwuji, GRB Irving, S Barber, H Walter, Z Sidat, ... The Journal of nutrition 149 (7), 1133-1139, 2019 | 181 | 2019 |
| Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study RG Owen, H McCarthy, S Rule, S d'Sa, SK Thomas, O Tournilhac, ... The Lancet Haematology 7 (2), e112-e121, 2020 | 149 | 2020 |
| Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy TA Eyre, HS Walter, S Iyengar, G Follows, M Cross, CP Fox, A Hodson, ... Haematologica 104 (2), e68, 2019 | 130 | 2019 |
| Targeting anti‐apoptotic BCL 2 family proteins in haematological malignancies–from pathogenesis to treatment M Vogler, HS Walter, MJS Dyer British journal of haematology 178 (3), 364-379, 2017 | 103 | 2017 |
| Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia IW Flinn, JG Gribben, MJS Dyer, W Wierda, MB Maris, RR Furman, ... Blood, The Journal of the American Society of Hematology 133 (26), 2765-2775, 2019 | 83 | 2019 |
| Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents LE Roeker, P Dreger, JR Brown, OB Lahoud, TA Eyre, DM Brander, ... Blood advances 4 (16), 3977-3989, 2020 | 75 | 2020 |
| Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post‐BCR inhibitor setting: a UK wide analysis TA Eyre, AA Kirkwood, S Gohill, G Follows, R Walewska, H Walter, ... British journal of haematology 185 (4), 656-669, 2019 | 73 | 2019 |
| Phase Ib study of tirabrutinib in combination with idelalisib or entospletinib in previously treated chronic lymphocytic leukemia AV Danilov, C Herbaux, HS Walter, P Hillmen, SA Rule, EA Kio, L Karlin, ... Clinical Cancer Research 26 (12), 2810-2818, 2020 | 61 | 2020 |
| COVID-19 in patients with CLL: improved survival outcomes and update on management strategies LE Roeker, TA Eyre, MC Thompson, N Lamanna, AR Coltoff, MS Davids, ... Blood, The Journal of the American Society of Hematology 138 (18), 1768-1773, 2021 | 60 | 2021 |
| Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059 HS Walter, S Jayne, SA Rule, G Cartron, F Morschhauser, S Macip, ... Blood, The Journal of the American Society of Hematology 129 (20), 2808-2810, 2017 | 59 | 2017 |
| Responses to the selective Bruton’s tyrosine kinase (BTK) inhibitor tirabrutinib (ONO/GS-4059) in diffuse large B-cell lymphoma cell lines R Kozaki, M Vogler, HS Walter, S Jayne, D Dinsdale, R Siebert, MJS Dyer, ... Cancers 10 (4), 127, 2018 | 36 | 2018 |
| Optimizing platelet GPVI inhibition versus haemostatic impairment by the Btk inhibitors ibrutinib, acalabrutinib, ONO/GS-4059, BGB-3111 and evobrutinib V Denzinger, K Busygina, J Jamasbi, I Pekrul, M Spannagl, C Weber, ... Thrombosis and Haemostasis 119 (03), 397-406, 2019 | 35 | 2019 |
| A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer. ER Plummer, RS Kristeleit, E Cojocaru, NM Haris, L Carter, RH Jones, ... Journal of Clinical Oncology 37 (15_suppl), 3094-3094, 2019 | 33 | 2019 |
| Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen MC Thompson, RA Harrup, CC Coombs, LE Roeker, JJ Pu, MY Choi, ... Blood advances 6 (15), 4553-4557, 2022 | 32 | 2022 |
| Phase I expansion study of the first-in-class monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma … SER Halford, H Walter, P McKay, W Townsend, K Linton, K Heinzmann, ... Journal of Clinical Oncology 39 (15_suppl), 3115-3115, 2021 | 25 | 2021 |
| Targeted therapies in cancer HS Walter, S Ahmed Surgery (Oxford) 36 (3), 122-127, 2018 | 25 | 2018 |
| A phase I/II trial of oral SRA737 (a Chk1 Inhibitor) given in combination with low-dose gemcitabine in patients with advanced cancer R Jones, R Plummer, V Moreno, L Carter, D Roda, E Garralda, R Kristeleit, ... Clinical Cancer Research 29 (2), 331-340, 2023 | 24 | 2023 |
